Silence Therapeutics appoints Tim McInerney to board; James Ede-Golightly to retire at June 2025 AGM

Silence Therapeutics plc

Tim McInerney appointed director effective May 5, 2025; will chair Remuneration Committee and join Audit and Risk Committee.
James Ede-Golightly to retire at end of his term at 2025 AGM (June 26); steps down as Remuneration Committee chair immediately.
McInerney receives $56,000 annual retainer, initial option for 48,000 ordinary shares (36-month monthly vest), and annual grant of same.
McInerney brings 30+ years pharma/healthcare investment banking and executive experience; served on boards of Emisphere, Insite Vision, etc.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Tim McInerney

Director

SLN · Silence Therapeutics plc

Effective: 2025-05-05
Filed: May 6, 2025, 7:59 PM ET

On May 5, 2025, upon the recommendation of the Nominations Committee, the Board appointed Tim McInerney to serve as a director of the Company, effective immediately.

Departed

James Ede-Golightly

Director

SLN · Silence Therapeutics plc

Effective: 2025-06-26
Filed: May 6, 2025, 7:59 PM ET

On May 5, 2025, James Ede-Golightly notified the board of directors (the “ Board ”) of Silence Therapeutics plc (the “ Company ”) of his decision to retire from the Board following the end of his current term, which expires at the end of the Company’s 2025 Annual General Meeting of Shareholders, which is anticipated to be held on June 26, 2025 (the “ 2025 AGM ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tim McInerney was appointed as Director at Silence Therapeutics plc.

Action: appointed
Role: Director

Exact text from the filing

On May 5, 2025, upon the recommendation of the Nominations Committee, the Board appointed Tim McInerney to serve as a director of the Company, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

James Ede-Golightly departed as Director at Silence Therapeutics plc.

Action: retire
Role: Director

Exact text from the filing

On May 5, 2025, James Ede-Golightly notified the board of directors (the “ Board ”) of Silence Therapeutics plc (the “ Company ”) of his decision to retire from the Board following the end of his current term, which expires at the end of the Company’s 2025 Annual General Meeting of Shareholders, which is anticipated to be held on June 26, 2025 (the “ 2025 AGM ”).

View on SEC.gov

Silence Therapeutics plc filing history →

Source: SEC EDGAR

accession 0001193125-25-113364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.